In VivoThree years after In Vivo identified AI in biologics as “an emerging frontier,” pharmaceutical companies are doubling down with billion-dollar partnerships and comprehensive internal platforms. Ye
In VivoBarcelona-based Almirall SA is deepening its reliance on generative artificial intelligence (GenAI) for drug discovery and development. The company, which specializes in dermatological indications,
In VivoIn early December, AstraZeneca PLC announced a $247m alliance with generative artificial intelligence biologics development company, AbSci Corp. , to design an antibody against an unnamed oncology
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Vanda To Pay $100m For Rights To MS The